FindTrial
Sign In

Tissue sampling

OTHER7 trials

Sponsors

Professor Michael Bourke, University of Catanzaro, Netherlands Working Group on Immunotherapy of Oncology, Niels Fristrup, Gustave Roussy, Cancer Campus, Grand Paris

Conditions

CancerDuodenal DiseasesExtracellular Matrix AlterationHEMORRHOIDSKidney CancerMetastatic MelanomaPulmonary HypertensionRenal Cell Carcinoma Metastatic

Phase 2

Vemurafenib Plus Cobimetinib in Metastatic Melanoma
TerminatedNCT02414750
Netherlands Working Group on Immunotherapy of OncologyMetastatic Melanoma
Start: 2014-12-31End: 2020-11-30Updated: 2022-11-30

Unknown Phase

Endoscopic Characteristics of Duodenal and Ampullary Lesions
CompletedNCT01556399
Professor Michael BourkeDuodenal Diseases
Start: 2011-11-30End: 2018-11-30Updated: 2025-03-27
Hemorrhoids and Metalloproteinases, Observational Study
CompletedNCT02358174
University of CatanzaroExtracellular Matrix Alteration, HEMORRHOIDS
Start: 2013-09-30End: 2014-12-31Updated: 2015-02-06
Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial
RecruitingNCT03977571
Niels FristrupKidney Cancer, Renal Cell Carcinoma Metastatic, Synchronous Neoplasm
Start: 2020-07-06End: 2031-12-01Target: 400Updated: 2026-05-04
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
NCT04349293
Gustave Roussy, Cancer Campus, Grand ParisCancer
Start: 2016-09-08End: 2021-09-30Target: 150Updated: 2020-04-16
Inflammatory Profiling in Chronic Lung Disease
RecruitingNCT04654767
Ludwig Boltzmann Institute for Lung Vascular ResearchPulmonary Hypertension
Start: 2021-12-01End: 2025-06-30Target: 60Updated: 2024-04-16
Evaluation of Bile Acid Concentrations and Their Signaling as Markers of Testicular Tumorigenesis and Germ Cell Tumor Chemosensitivity
RecruitingNCT07463508
University Hospital, Clermont-FerrandTesticular Germ Cell Cancer
Start: 2026-01-01End: 2029-01-01Target: 20Updated: 2026-03-11

Related Papers

Abstract 4141: Multimodal single-cell analysis of systemic immune remodeling induced by cytoreductive nephrectomy combined with immune checkpoint inhibitors in metastatic renal cell carcinoma
Cancer Research2026-04-03
Cytoreductive nephrectomy in the era of immune-checkpoint inhibitors: back to the future?
2026-02-11
Metabolic parameters on baseline and early [<sup>18</sup>F]FDG PET/CT as a predictive biomarker for resistance to BRAF/MEK inhibition in advanced cutaneous BRAFV600-mutated melanoma.
2025-05-28
‘Case of the Month’ from Addenbrooke's Hospital, Cambridge, <scp>UK</scp> : surgery after near complete response to combined immunotherapy and tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma with inferior vena cava tumour thrombus
British Journal of Urology2024-07-16
The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in immune-oncology era (SEVURO-CN): study protocol for a multi-center, prospective, randomized trial.
2024-07-037 citations
Cytoreductive surgery, systemic treatment, genetic evaluation, and patient perspective in a young adult with metastatic renal cell carcinoma
CA A Cancer Journal for Clinicians2024-04-033 citations
Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial.
2024-02-2425 citations
Surgical and focal treatment for metastatic renal cell carcinoma: A literature review.
2022-03-269 citations
Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy.
2021-05-0118 citations
Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study.
2017-09-1515 citations